Related Experiment Videos
Thiamine for Alzheimer's disease
J L Rodríguez-Martín1, N Qizilbash, J M López-Arrieta
1Iberoamerican Cochrane Centre, Department of Epidemiology, Hospital de la Santa Creu i Sant Pau, Sant Antoni M feminine Claret, 171, Barcelona, Catalunya, Spain, 08041. jrodriguezma@hsp.santpau.es
The Cochrane Database of Systematic Reviews
|June 19, 2001
Summary
This review found insufficient evidence to conclude if Vitamin B1 (thiamine) benefits Alzheimer's disease patients. More research is needed due to limited data and small study sizes.
Area of Science:
- Neurology
- Nutritional Neuroscience
Background:
- Vitamin B1 (thiamine) is crucial for preventing Wernicke-Korsakoff syndrome.
- Thiamine deficiency can lead to severe neurological impairment.
- Preliminary suggestions indicated potential benefits of thiamine in Alzheimer's disease.
Purpose of the Study:
- To systematically review the efficacy of thiamine in treating Alzheimer's disease.
Main Methods:
- Searched multiple databases (Cochrane, CDCIG) for randomized, double-blind, placebo-controlled trials of thiamine in Alzheimer's patients.
- Included trials administering thiamine for over 24 hours.
- Extracted data and estimated effect sizes (odds ratios or average differences).
Main Results:
- Three studies were included, but reported results were minimal and could not be pooled for meta-analysis.
- One study showed no significant effect of thiamine on MMSE scores at various time points.
- Another study indicated a non-significant trend towards worsening on ADAS-Cog for thiamine compared to placebo.
Conclusions:
- Current evidence is insufficient to determine thiamine's efficacy for Alzheimer's disease.
- The small number of participants (under 50) and inadequate reported results limit definitive conclusions.
- Further high-quality research is required to assess thiamine's therapeutic potential.